Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction

Hamdy MA Ahmed1 Internal Medicine Department, Rochester General Hospital, Rochester, NY, USA, [email protected];2 Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, [email protected];3 Rheumatology and Clinical Immunology Division, Internal Medicine Department, University of Alabama at Birmingham, Birmingham, AL, USA, [email protected]Correspondence[email protected]

Samar Abohamad2 Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, [email protected]

Mohanad Elfishawi4 Internal Medicine Department, Queens Hospital Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Mohamed Tharwat Hegazy2 Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, [email protected]

Kadambari Vijaykumar1 Internal Medicine Department, Rochester General Hospital, Rochester, NY, USA, [email protected];5 Pulmonology and Critical Care Division, Internal Medicine Department, University of Alabama at Birmingham, Birmingham, AL, USA

Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction

Figures & data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date